A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting AntiviralNave Subjects with Chronic HCV Infection
A study for patients with Chronic HCV Infection using study drug combination Sofosbuvir/Velpatasvir/GS-9857
Sponsor: Gilead
Enrolling: Male and Female Patients
IRB Number: AAAQ4053
U.S. Govt. ID: NCT02607800
Contact: Theresa Lukose: 212-305-6758 / tt2103@cumc.columbia.edu
Additional Study Information: The purpose of this study is to evaluate the effectiveness, safety, and tolerability of study drugs Sofosbuvir, Velpatasvir and GS-9857 in comparison to Sofosbuvir and Velpatasvir in patients infected with HCV. Information about any side effects that may occur will also be collected.
This study is closed
Investigator
Elizabeth Verna, MD
Do You Qualify?
Have you been diagnosed with Chronic HCV Infection? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Theresa Lukose
tt2103@cumc.columbia.edu
212-305-6758
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE